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Aims A marked increase in HDL notwithstanding, the cholesterol ester transfer protein (CETP) inhibitor torcetrapib was
associated with an increase in all-cause mortality in the ILLUMINATE trial. As underlying mechanisms remain elusive,
the present study was designed to delineate potential off-target effects of torcetrapib.
Methods
and results
Spontaneously hypertensive rats (SHRs) and Wistar–Kyoto (WKY) rats were treated with torcetrapib (100 mg/kg/
day; SHR-T and WKY-T) or placebo (SHR-P and WKY-P) for 3 weeks. Blood pressure transiently increased during
the first 3 days of torcetrapib administration in SHRs and returned to baseline thereafter despite continued drug
administration. Acetylcholine-induced endothelium-dependent relaxations of aortic rings were markedly impaired,
and endothelial nitric oxide synthase (eNOS) mRNA and protein were down-regulated after 3 weeks of torcetrapib
treatment in SHR (P, 0.0001, ,0.01, and ,0.05, resp. vs. SHR-P). Torcetrapib reduced NO release in cultured
aortic endothelial cells (P, 0.01 vs. vehicle-treated cells) and increased generation of reactive oxygen species in
aortas of SHR-T (P, 0.05, vs. SHR-P). Vascular reactivity to endothelin-1 (ET-1) and aortic ET-1 tissue content
were increased in SHR-T (P, 0.05 vs. SHR-P). Importantly, the ET-1 receptor A/B (ETA/B) antagonist bosentan nor-
malized endothelial function in SHR-T (P, 0.05).
Conclusion Torcetrapib induces a sustained impairment of endothelial function, decreases eNOS mRNA, protein as well as NO
release, stimulates vascular ROS and ET production, an effect that is prevented by chronic ETA/B-receptor blockade.
These unexpected off-target effects of torcetrapib need to be ruled out in the clinical development of novel CETP
inhibitors, particularly before a large patient population at increased cardiovascular risk is exposed to these
compounds.
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Introduction
The plasma levels of high-density lipoprotein (HDL) cholesterol are
inversely related to cardiovascular risk.1–3 Currently available
HDL-raising therapies are associated with undesirable side effects,
limited efficacy, or have not yet been shown to improve morbidity
and mortality on top of statins in clinical outcome trials.4–6 A novel
pharmacological target for raising circulating HDL-C levels is the
cholesterol ester transfer protein (CETP), an enzyme involved in
the physiological process of reverse cholesterol transport in
humans, by which excess cholesterol is removed from peripheral
tissues, and then returned to the liver for secretion into the bile.
Conceptually, inhibition of CETP thus provides an attractive thera-
peutic target.7 Indeed, three pharmacological small-molecule inhibi-
tors of CETP, i.e. dalcetrapib (JTT-705; Roche), anacetrapib (Merck),
and torcetrapib (Pfizer), have been developed. The molecules effec-
tively raise HDL-C by 60–100% in humans either when used as a
monotherapy or in combination with statins.
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Surprisingly and in spite of a marked increase in HDL-C and a
reduction in LDL-C levels, an unexpected increase in all-cause mor-
tality, including cardiovascular and non-cardiovascular events, was
observed in patients treated with torcetrapib in the Investigation of
Lipid Level Management to Understand Its Impact in Atherosclerotic
Events (ILLUMINATE) study.8 Furthermore, three large imaging trials
using coronary intravascular ultrasound and carotid intima-media
thickness demonstrated a lack of efficacy of torcetrapib on coronary
atheroma burden or carotid intima-media thickness, respectively,
again in spite a marked increase in HDL levels.9–11 The molecular
mechanisms for this excess in cardiovascular morbidity and mortality
and lack of anti-atherosclerotic efficacy remain still elusive.
It is of note that the use of torcetrapib was associated with an
increase in blood pressure (BP) in ILLUMINATE as well as in clini-
cal trials of the early development phase.9– 13 As the potent CETP
inhibitors dalcetrapib and anacetrapib are devoid of such pressor
effects,14– 17 the BP elevation associated with torcetrapib may rep-
resent an off-target effect specific for this molecule. Importantly, in
the ILLUMINATE study, a moderate decrease in potassium and
slight increase in sodium and bicarbonate was observed in the tor-
cetrapib group, suggesting a potential mineralocorticoid effect of
torcetrapib.8
Thus, the aim of the present study was to delineate underlying
potential off-target effect(s) of torcetrapib in experimental hyper-
tension. As endothelial function may be an obvious target of the
compound, we investigated specifically, whether and to what
degree torcetrapib impacts on this well-established surrogate for
cardiovascular risk.
Methods
Animals
Male spontaneously hypertensive rats (SHRs) and Wistar–Kyoto
(WKY) rats, 16–20 weeks old, mean weight 320 g, were purchased
from Charles River Laboratories (Research Models and Services,
Germany GmbH). Animals were fed a normal chow diet and had
ad libitum access to food and water, maintained at 248C under a
12 h light/dark cycle. Torcetrapib (CP-529414 Spray-dried dispersion,
LOT ID FP-04-069, kindly provided by Pfizer Inc., Groton, CT, USA)
or placebo was given as a suspension in 0.5% methyl cellulose in a
final concentration 100 mg/kg/day p.o. (oral gavage), for a total dur-
ation of 3 weeks. Dosage of torcetrapib was adjusted for body
weight and calculated on a daily basis. In addition, animals were
co-treated with the endothelin (ET)-receptor antagonist bosentan
100 mg/kg/day (Actelion Pharmaceuticals Ltd, Switzerland) together
with torcetrapib. Systolic BP and heart rate were measured by tail-cuff
method (model LE 5002, Storage Pressure Meter, Letica, Spain) after
intensive training of the animals.
Study design and experimental protocols fully complied with the
guidelines for research animal use by the American Heart Association
and were approved by the institutional animal care committee (Licence
Nr. 17/2008, Kommission fu¨r Tierversuche des Kantons Zu¨rich,
Switzerland).
Tissue harvesting and organ chamber
experiments
At the end of the 21-day treatment, animals were first anaesthetized
using pentobarbital (50 mg/kg i.p.) and sacrificed by blood
exsanguinations. Blood was drawn into Li-Heparin-coated vacutainers
(Vacutainerw Heparin Tubes, Additive Lithium Heparin (68 USP),
BD) and plasma was isolated. Aorta was removed and placed in cold
(48C) modified Krebs–Ringer bicarbonate solution.
The aorta was cleaned from connective tissue and cut into rings of
3 mm length. The remaining aortic tissue was snap frozen in liquid
nitrogen for further analysis. Aortic rings were placed in an organ
bath for isometric tension recording as described elsewhere.18
Shortly after 60 min of an equilibration, the rings were progressively
stretched to their optimal passive tension (3 g). Rings were pre-
constricted with norepinephrine (NE, 70% of 100 mM KCl) and
relaxations to acetylcholine (ACh, 10210 to 1025 M) or sodium nitro-
prusside (SNP, 10210 to 1025 M) were obtained. In additional exper-
iments, vasoconstriction to ET-1 (10210 to 1021 M) and
concentration–response curves to NE (10210 to 1025 M) were
obtained. In addition, vascular reactivity to ET-1 was performed in
the presence of selective ET-1 receptor A (ETA) and ET-1 receptor
B (ETB) antagonists, BQ-123 and BQ-788 (10
26 M), respectively, pre-
incubating the rings with the antagonists for 30 min before ET-1 was
added.
All organ chamber experiments were performed in the presence of
indomethacin (1025 M), a non-selective inhibitor of cyclooxygenase-1
and -2 (COX-1 and COX-2, respectively). Chemicals used in the organ
bath were obtained from Sigma Aldrich (Buchs, Switzerland)
apart from ET-1 and big ET-1, which were purchased from Bachem
(Bubendorf, Switzerland). After experiments, vessel rings were
blotted dry and weighted.
RNA and Western blot
RNA was extracted from frozen aortic tissue pulverized on a stainless
steel mortar by hammering. Purification of total RNA was performed
as described in RNeasyw Mini Handbook (Qiagen AG, Hombrechti-
kon, Switzerland). The primers and probe used for RT–PCR analysis
were: rat endothelial nitric oxide synthase (eNOS), forward primer:
5′-CTA CCG GGA CGA GGT ACT GG-3′, backward primer:
5′-GGA AAA GGC GGT GAG GAC TT-3′ (Microsynth Balgach,
Switzerland), probe: 5′-CGC CCA GCA GCG TGG AGT GTT T-3′ ,
5′-End Fam, 3′-TAMRA Probe, (Applied Biosystems Rotkreuz,
Switzerland), human vascular cell adhesion molecule 1 (VCAM-1):
forward: 5′-GTC TCC AAT CTG AGC AGC AA-3′,backward:
5′-TGG GAA AAA CAG AAA AGA GGT G- 3′ , human inter-cellular
adhesion molecule 1 (ICAM-1): forward: 5′-AGG GTA AGG TTC
TTG CCC AC-3′, backward: 5′-TGA TGG GCA GTC AAC AGC
TA-3′, human L28: forward: 5′-GCA ATT CCT TCC GCT ACA
AC-3′, backward: 5′-TGT TCT TGC GGA TCA TGT GT-3′, rat
VCAM-1: forward: 5′-GCG AAG GAA ACT GGA GAA GAC A- 3′ ,
backward: 5′-ACA CAT TAG GGA CCG TGC AGT T- 3′, rat
ICAM-1: forward: 5′-TTT CGA TCT TCC GAC TAG GG-3′, back-
ward: 5′-AGC TTC AGA GGC AGG AAA CA-3′, rat iNOS:
forward: 5′-CAG ATC CCG AAA CGC TAC AC-3′, backward:
5′-TGC GGC TGG ACT TCT CAC T-3′, rat GAPDH:
forward: 5′-TGC CAA GTA TGA TGA CAT CAA GAA G- 3′ , back-
ward: 5′-AGC CCA GGA TGC CCT TTA GT-3′(Microsynth AG,
Balgach, Switzerland).
Pulverized aortic tissue for Western blot analysis was further hom-
ogenized in the ice-cold lysis buffer [150 mM NaCl, 50 mM Tris, pH
7.4, 1% NP-40, 1 mM EDTA, 1 Protease Inhibitor Cocktail Tablet
(Roche complete EDTA-free, Roche, Switzerland), phosphatase inhibi-
tor cocktail 1 and 2 (Sigma Aldrich, Buchs, Switzerland)]. Protein
extract concentration was measured by the Bradford method19 and
50 mg of protein extract was loaded on a 10% polyacrylamide–SDS
gel for electrophoresis, as described previously.20 Endothelial NO
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synthase was detected using eNOS antibody (eNOS, SantaCruz, 1:200;
28:antirabbit-POD, 1:2500, GE Healthcare, UK), and for a normaliza-
tion b-actin antibody was used (b-actin, Sigma, 1:20 000; 28:antimouse-
POD, 1:20 000, GE Healthcare, UK). Blot visualization was performed
by ImageReader Fuji Film LAS-300 (FujiFilm Corporation, Tokyo,
Japan). Quantification of the band intensities was performed using
AIDA Image Analyzer software (Raytest Schweiz AG, Wetzikon, Swit-
zerland). For expression analysis of the adhesion molecules following
antibodies were used: human VCAM-1: anti hVCAM-1, BBA19, R&D
Systems (18Ab-1:1000; 28Ab-1:2500), human ICAM-1: anti- CD54
(ICAM-1), 07-5403, Invitrogen (18Ab-1:1000; 28Ab-1:5000), rat
VCAM-1: VCAM-1 (C-19), sc-1504, Santa Cruz Biotechnology, Inc.
(18Ab-1:500; 28Ab-1:5000), rat ICAM-1: ICAM-1 (M-19), sc-1511,
Santa Cruz Biotechnology, Inc. (18Ab-1:500; 28Ab-1:5000), rat iNOS:
NOS2 (H-174), sc-8310, Santa Cruz Biotechnology, Inc. (18Ab-1:500;
2Ab-1:5000), GAPDH: anti-GAPDH, MAB374, Millipore
(18Ab-1:10 000; 28Ab-1:20 000).
Endothelin-1 determination
Tissue ET-1 level was determined as described previously.21 Briefly,
tissue was hydrolyzed in 0.1 M acetic acid at 808C, and then thoroughly
homogenized using a polytron homogenizer. After centrifugation,
extraction was performed using a standard peptide extraction pro-
cedure, by adsorption on prewashed Sep-Pak Vac C18 (500 mg) car-
tridges (Millipore). The ET-1 level was determined using
radioimmunoassay and the recording was done using a g counter
and the radioimmunoassay data processed using machine software
(Canberra Packard).
Immunohistochemistry
Prior to histological analysis, samples were embedded in Tissue-Tekw
O.C.T.TM compound (Sakura Finetek Europe, Zoeterwoude, the Neth-
erlands), frozen on dry ice and stored at 2808C. Cryosections of rat
aortas (7 mm) were fixed with freshly prepared 4% paraformaldehyde
on SuperFrostw (SuperFrost, Braunschweig, Germany) slides.
Endogenous peroxidase activity was blocked by dipping the slides for
5 min in a 3% H2O2–methanol solution. Slides were further incubated
in a humid chamber at 48C overnight with or without first antibody
against rat ETA and ETB receptors (1:10 dilution; Alomone Labs Ltd,
Jerusalem, Israel). After washing in phosphate-buffered saline, affinity-
purified biotin-conjugated goat anti-rabbit antibody (Dako, Glostrup,
Denmark) was applied for 60 min at room temperature in a humid
chamber. Slides were then exposed to avidin–biotin–horseradish per-
oxidase complex prepared from the reagents supplied by Dako
(Glostrup, Denmark, Cat. no. KO355) during 45 min. Bound peroxi-
dase was detected after 3 min incubation at room temperature with
3,3′-diaminobenzidine substrate (Sigma, St Louis, MO, USA). Sections
were finally counterstained briefly with haematoxylin (Merck,
Darmstatt) and mounted in Aquatex (Merck).
Intensity was scored by an independent observer in at least three
different samples and unaware of the groups and treatments. In
order to evaluate the integrity of the endothelium and vascular
smooth muscle layers, some samples were stained with von Willeb-
rand factor (Dako) and smooth muscle actin (Dako). To evaluate poss-
ible background reactions, procedures were also performed in
sections incubated with the provided control peptide antigen
(Alomone Labs Ltd.) in excess.
Plasma electrolytes and lipids
Plasma electrolytes (Na+, K+, and Cl2) and plasma lipids (HDL-C,
LDL-C, and total cholesterol) were determined using standard
enzymatic method on an automated analyser (Hitachi 912, Roche
Diagnostics AG system, Rotkreuz, Switzerland).
Plasma aldosterone, renin, and angiotensin II
levels
Plasma aldosterone, renin, and angiotensin levels were determined
using commercially available ELISA kits (aldosterone: Alpha Diagnostic
International, San Antonio, TX, USA; renin and angiotensin II: Cusabio
Biotech Co., Ltd, Newark, DE, USA).
Cell culture
Human aortic endothelial cells (HAECs) were obtained from Clone-
ticsw. In 60-mm culture dishes, HAECs were grown in endothelial
basal medium (Cloneticsw), in a humidified atmosphere (378C, 95%
air /5% CO2). Media was supplemented with 10% Foetal calf serum
and EGMTM-2 SingleQuotsw (Cat. no. CC-4176, Cloneticsw). After
confluence, cells were rendered quiescent by incubation in medium
with 0.5% serum for 24 h and then stimulated with vehicle methanol
and torcetrapib pure drug (CP-529414, Lot ID 052301-001-21,
Pfizer Inc.) for additional 24 h. At 24 h time point, 1000 mL media
were removed from each dish for the cell viability assay using Cytotox-
icity Detection Kit (LDH, Cat. no. 11 644 793 001, Roche). Cells were
lysed in ice cold lysis buffer as described above. Lysates were frozen at
2808C until Western blot analysis.
Measurement of endothelial cell nitric oxide
production by electron spin resonance
spectroscopy
The effects of torcetrapib (1000 nM; 24 h at 378C) on endothelial NO
production (HAECs; passage number 4–6; Cloneticsw) was examined
by electron spin resonance (ESR) spectroscopy using the spin-probe
colloid Fe(DETC)2 (Noxygen, Elzach, Germany), as described
previously.22 In brief, ESR spectra of samples frozen in liquid nitrogen
were recorded on a Bruker e-scan spectrometer (Bruker BioSpin,
Billerica, MA, USA) with the following instrumental settings: centre
field (B0) 3455 G, sweep width 80 G, microwave power 39.72 db,
amplitude modulation 10.34 G, sweep time 10.49 s, and number of
scans 10. The intensity values for NO were normalized to the
amount of protein within each sample, as detected by the Bio-Rad
Protein assay (Reinach, Switzerland).
Measurement of superoxide production in rat
aorta by electron spin resonance
spectroscopy
Superoxide production was determined in rat descending aorta
sections by ESR spectroscopy using the spin probe
1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-1-pyrrolidine and
an e-scan ESR spectrometer (Bruker BioSpin). Time-dependent for-
mation of superoxide was analysed using the following instrumental
settings: centre field 1.99 g, microwave power 20 mW, modulation
amplitude 2 G, sweep time 60 s, field sweep 60 G. The intensity of
ESR spectra was quantified after calibration of ESR signals with the
free radical 3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxy. The
intensity values were divided by the dry weight of aorta sections.
Calculations and statistical analysis
Data are presented as mean+ SEM. Contraction or relaxation (as per
cent pre-contraction in rings pre-contracted to 70–80% of contraction
induced by potassium chloride, 100 mM), negative logarithm of the
concentration causing half-maximal relaxation or contraction (EC50
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value), and area under the curve were determined for each individual
dose–response curve by non-linear regression analysis using GraphPad
Prism 5.0 software for Windows (GraphPad Software, San Diego, CA,
USA, www.graphpad.com). For comparing two groups, an unpaired
Student’s t-test was applied and, for multiple comparisons, the
one-way ANOVA was used, followed by unpaired t-test for
two-group-comparisons, when the ANOVA was significant. All statisti-
cal tests used were two sided. A value of P, 0.05 was considered
significant.
Results
Animal characteristics and general data
Systolic blood pressure
Body weight and systolic BP were monitored throughout the entire
duration of the study (Table 1). Systolic BP was elevated for 3 days
after the start of torcetrapib administration in SHRs (P, 0.05), but
not in WKY rats. However, BP returned to baseline after the third
day and remained at initial levels despite continuous drug adminis-
tration (Figure 1A). No change in BP was observed in WKY rats
(Figure 1B).
Torcetrapib plasma levels
Plasma levels of torcetrapib were determined by UPLC-ESI-MS.
The values averaged 0.648 and 0.820 mg/mL, respectively, in
SHR-T and WKY-T (Table 2).
Plasma electrolytes and lipids
Plasma levels of K+ and Cl2 were comparable for all groups. There
was a tendency for lower Na+ levels in SHR-T (P ¼ 0.059 vs.
SHR-P). No difference was detectable in WKY rats (Table 2).
Plasma lipid levels remained unchanged (Table 2).
Activity of the endothelial L-arigine/nitric
oxide pathway
Expression of endothelial nitric oxide synthase, VCAM-1,
and ICAM-1 in cultured human aortic endothelial cells
Torcetrapib pure drug was used in cultured HAECs to investigate
changes in NO bioavailability in vitro. The cell viability assay showed
no torcetrapib-induced cellular toxicity (10–3000 nM, Figure 2A).
A marked down-regulation of total eNOS protein in HAECs
treated with torcetrapib was observed (227.16, 235.35,
237.09, and 237.74%, for 100, 500, 1000, and 3000 nM torcetra-
pib, respectively; P, 0.05, for all torcetrapib concentrations vs.
vehicle-treated cells) (Figure 2B). Both VCAM-1 and ICAM-1
were not differentially regulated in HAECs treated with torcetrapib
vs. vehicle-treated HAECs, both at RNA and protein level (see
Supplementary material online, Figure S6).
Nitric oxide release in cultured human aortic
endothelial cells
In HAECs treated with torcetrapib, a marked reduction in NO
release was observed as assessed by ESR spectroscopy
(227.06%, P, 0.01 vs. vehicle-treated cells) (Figure 2C).
Aortic expression of endothelial nitric oxide synthase,
inducible nitric oxide synthase, VCAM-1, and ICAM-1
Torcetrapib decreased eNOS mRNA and eNOS protein expression
in the aortas of SHR as assessed by quantitative real-time PCR and
Western blot analysis (243.91, P ¼ 0.008; 245.74, P ¼ 0.049, vs.
SHR-P, resp.) (Figure 3A and B). No difference in eNOS
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Table 1 The main parameters analysed in torcetrapib-treated spontaneously hypertensive rats (SHR-T), placebo
spontaneously hypertensive rats (SHR-P), torcetrapib-treated Wistar–Kyoto rats (WKY-T), and placebo Wistar–Kyoto
rats (WKY-P)
Parameter SHR-T SHR-P WKY-T WKY-P
Systolic blood pressure
(mmHg)-area under the curve
194.3+0.601*, n ¼ 21 190.5+0.292, n ¼ 19 122.3+0.192, n ¼ 17 121.4+0.161, n ¼ 13
Body weight (g)
Day 1 308.3+6.039 313.9+9.867 294.3+5.420 307.8+4.871
Day 21 330.6+8.017 345.8+10.860 331.3+12.350 361.0+7.703
Acetylcholine
Area under the curve 191.9+7.844†, n ¼ 11 241.6+5.560, n ¼ 11 234.6+9.371, n ¼ 4 244.1+7.317, n ¼ 4
EC50 (M), 2log 7.736+0.062
‡, n ¼ 12 7.989+0.056, n ¼ 11 7.669+0.061, n ¼ 4 7.743+0.050, n ¼ 4
Maximum (%) 73.48+1.347§ 83.34+0.949 88.37+1.018 88.37+1.111
Endothelin-1
Area under the curve 128.8+11.390}, n ¼ 12 96.84+8.332, n ¼ 10 106.6+6.300, n ¼ 6 97.17+3.289, n ¼ 4
EC50 (M), 2log 7.998+0.044, n ¼ 9 7.965+0.062, n ¼ 7 7.890+0.058, n ¼ 6 7.765+0.043, n ¼ 4
*P, 0.05 SHR-T vs. SHR-P;
†P, 0.0001 SHR-T vs. SHR-P;
‡P, 0.01 SHR-T vs. SHR-P;
§P, 0.0001 SHR-T vs. SHR-P;
}P, 0.05 SHR-T vs. SHR-P.
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gene expression was found in torcetrapib-treated WKY rats
(P ¼ 0.5206 vs. placebo-treated WKY rats) (Figure 3C). Both
VCAM-1 and ICAM-1 were not differentially expressed in aortas
of SHR-T and SHR-P, both at RNA and protein level (see Sup-
plementary material online, Figure S7). Furthermore, iNOS
expression was not changed in torcetrapib-treated SHR vs. placebo-
treated SHR (see Supplementary material online, Figure S8).
Endothelium-dependent and endothelium-independent
relaxation
Torcetrapib induced impairment of endothelium-dependent relax-
ation to ACh in isolated aortic rings from SHR-T pre-contracted
with NE (P, 0.0002 for 1029 M ACh, and P, 0.0001 for 1028,
1027, 1026, and 1025 M ACh vs. SHR-P, Figure 4). Dose–response
curves were used to determine EC50 value (2log[M ]) between
torcetrapib- and placebo-treated SHRs which were 7.736 and
7.989, for SHR-T and SHR-P, respectively (P ¼ 0.0069). The
area under the curve (AUC) was reduced in SHR-T (220.57%,
P, 0.0001 vs. SHR-P, Table 1) as well as the maximal response
(211.83%, P, 0.0001 vs. SHR-P). No difference in ACh-induced
endothelium-dependent relaxation was observed between the
rings isolated from torcetrapib-treated and placebo-treated WKY
rats, respectively (Figure 4).
Endothelium-independent vasorelaxation to SNP (10210–
1025 M) did not reveal any difference between SHR-T and
SHR-P (data not shown).
Generation of reactive oxygen species
To investigate the effects of tocretrapib on oxidative stress in vivo,
the generation of reactive oxygen species (ROS) was measured in
aortas of torcetrapib-treated (SHR-T) and placebo SHR (SHR-P)
using ESR spectroscopy. The aortas of SHR treated with torcetra-
pib showed an increase in ROS production as assessed by ESR
spectroscopy (+83.5%, P, 0.05 vs. SHR-P) (Figure 5).
Figure 1 Change in blood pressure of spontaneously hyper-
tensive rats (A) and normotensive Wistar–Kyoto rats (B). Systolic
blood pressure was increased during the first 3 days of torcetra-
pib administration only in spontaneously hypertensive rats receiv-
ing the drug, and despite continued drug administration blood
pressure remained unchanged until the end of the treatment.
No change in blood pressure was observed in Wistar–Kyoto
rats. *P, 0.05 SHR-T vs. SHR-P for the first three days of torce-
trapib administration. SHR-T, torcetrapib-treated SHR; SHR-P,
placebo SHR; WKY-T, torcetrapib-treated WKY; WKY-P,
placebo WKY.
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Table 2 The main parameters analysed in torcetrapib-treated spontaneously hypertensive rats (SHR-T), placebo
spontaneously hypertensive rats (SHR-P), torcetrapib-treated Wistar–Kyoto rats (WKY-T), and placebo Wistar–Kyoto
rats (WKY-P). (n5 5–12)
Parameter SHR-T SHR-P WKY-T WKY-P
Plasma electrolytes, mM
K+ 6.933+0.367 6.764+0.314 8.240+0.512 7.880+0.397
Cl2 88.91+1.436 91.00+1.267 90.40+0.748 91.20+0.533
Na+ 144.2+0.964 147.0+1.000 142.0+0.633 143.2+1.340
Plasma lipids, mM
LDL-C 0.2091+0.013 0.2300+0.017 0.2300+0.015 0.2610+0.017
HDL-C 1.704+0.072 1.810+0.072 2.080+0.148 2.126+0.078
Total Cholesterol 2.347+0.079 2.565+0.081 2.532+0.202 2.736+0.125
Renin, mU/mL 997.3+291.800 653.3+149.200 n.d. n.d.
Torcetrapib, mg/mL 0.648+0.549 n.d. 0.820+0.924 n.d.
Angiotensin II, pg/mL 42.79+11.690 41.50+16.300 n.d n.d.
n.d., not determined.
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Figure 2 (A) Cell viability assay. Cell culture medium from
cells incubated with different torcetrapib concentrations
(10–3000 nM) for 24 h was tested for the presence of lactate
dehydrogenase (LDH). There was no difference in cell viability
with all tested torcetrapib concentrations. Pos. control, positive
control, the cell culture medium with added vehicle and Triton
X-100 (2% in assay medium). (B) Western blot analysis of
protein extracts from human aortic endothelial cells treated
with torcetrapib for 24 h. Western blot analysis confirmed down-
regulation of endothelial nitric oxide synthase protein in protein
extracts from human aortic endothelial cells treated with torce-
trapib in a broad concentration range. Torcetrapib- vs. vehicle-
treated cells: *P ¼ 0.0467, P ¼ 0.0165, P ¼ 0.0123, and
P ¼ 0.0165 for 100, 500, 1000, and 3000 nM torcetrapib, respect-
ively. (C) Nitric oxide release from human aortic endothelial cells
treated either with 1000 nm tocetrapib or vehicle for 24 h
measured by electron spin resonance spectroscopy. Human
aortic endothelial cells treated with torcetrapib released less
nitric oxide when compared with human aortic endothelial cells
treated with the vehicle, *P ¼ 0.0050.
Figure 3 Expression of total endothelial nitric oxide synthase
in aortic tissue of spontaneously hypertensive rats. (A) Reverse
transcriptase-polymerase chain reaction demonstrated a
marked downregulation of endothelial nitric oxide synthase
mRNA in the aorta of torcetrapib-treated spontaneously
hypertensive rats vs. placebo-treated spontaneously hyperten-
sive rats. **P, 0.01. (B) Western blot analysis confirmed
tissue down-regulation of endothelial nitric oxide synthase
protein in torcetrapib-treated spontaneously hypertensive rats
vs. placebo-treated spontaneously hypertensive rats.
*P, 0.05. (C) Expression level of endothelial nitric oxide
synthase in aortic tissue of Wistar–Kyoto rats. Reverse
transcriptase-polymerase chain reaction demonstrated no
change in the endothelial nitric oxide synthase gene expression
profile from the aorta of torcetrapib-treated Wistar–Kyoto
rats (WKY-T) vs. placebo-treated Wistar–Kyoto rats (WKY-
P) (P ¼ 0.5206).
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Activity of the vascular endothelin system
Vascular reactivity to endothelin-1
Endothelin-1-induced contractions (1028 and 1027 M) of isolated
aortic rings obtained from SHR-T were increased when
compared with those obtained from SHR-P (P ¼ 0.0279 and
0.0243, respectively) (Figure 6). The AUC was increased in
SHR-T (+33%, P, 0.05 vs. SHR-P, Table 1). The EC50 value
(2log[M ]) of aortic rings from SHR-T and EC50 value of SHR-P
were calculated and averaged 7.998 and 7.965, respectively
(Table 1). Vascular reactivity to ET-1 in WKY rats remained
unchanged after torcetrapib treatment (Figure 6).
Aortic endothelin tissue levels during torcetrapib
treatment
Tissue content of ET-1 in the aortas of SHR-T was increased
(+49.56%, P ¼ 0.0154 vs. SHR-P) (Figure 7). Endothelin-1 tissue
levels in WKY-T did not significantly differ from those obtained
in WKY-P (P ¼ 0.2764).
Aortic endothelin receptor expression during torcetrapib
treatment
The ETA gene expression level showed only a tendency for a
higher expression, whereas ETB gene expression tended to be
decreased in SHR-T when compared with SHR-P, as measured
by RT–PCR, but this difference was not statistically significant
(data not shown).
Immunohistochemistry of endothelin receptors
Staining intensity of all samples was evaluated based on two inde-
pendent sections. Endothelin receptor A staining was more pro-
nounced in the endothelium, neo-intima and tunica media of
SHR-T when compared with SHR-P (see Supplementary material
online, Figure S1A and B). Endothelin receptor B exhibited
equally pronounced staining in both the endothelium and neoin-
tima layers of SHR-T when compared with SHR-P (see Supplemen-
tary material online, Figure S2A and B). All controls, either achieved
by incubation with the specific control peptide, or using normal
controls analysed without primary antibodies, were negative
(see Supplementary material online, Figures S1C and S2C). von
Willebrand factor-staining and smooth muscle a-actin-staining
did not differ between SHR-T and SHR-P (data not shown). In
some sections, we observed background at the edge of disrupted
adventia which we considered insignificant taking into consider-
ation the small size of these samples.
The analysis of the staining intensities in endothelium cells and
vascular smooth muscle cells (VSMCs) for ETA and ETB receptors
Figure 4 Endothelium-dependent relaxation to acetylcholine
in isolated aortic rings pre-contracted with norepinephrine
obtained from spontaneously hypertensive rats and Wistar–
Kyoto rats. Acetylcholine-induced vasorelaxation was impaired
in aortas of torcetrapib-treated spontaneously hypertensive rats
(SHR-T) in comparison with placebo-treated spontaneously
hypertensive rats (SHR-P), (*P, 0.0001 for SHR-T vs. SHR-P)
and in SHR-P vs. WKY-P (§P ¼ 0.01).
Figure 5 Effect of torcetrapib on the generation of reactive
oxygen species in aortas of spontaneously hypertensive rats
treated with torcetrapib (SHR-T) when compared with placebo
spontaneously hypertensive rats (SHR-P). Reactive oxygen
species formation was increased in SHR-T (P ¼ 0.0411 vs.
SHR-P).
Figure 6 Dose–response curve to endothelin-1 in quiescent
isolated aortic rings obtained from spontaneously hypertensive
rats and Wistar–Kyoto rats. Endothelin-1-induced vasoconstric-
tion of isolated aortic rings obtained from torcetrapib-treated
spontaneously hypertensive rats (SHR-T) was increased com-
pared with those obtained from placebo-treated spontaneously
hypertensive rats (SHR-P), P, 0.05. No change was observed
between torcetrapib-treated Wistar–Kyoto rats and placebo-
treated Wistar–Kyoto rats.
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was performed using analySISw software (Soft Imaging System,
GmbH, Mu¨nich, Germany). No difference in the receptors’
density in either endothelium or VSMCs was found for ETA or
ETB receptors (see Supplementary material online, Figure S3A, B,
and C).
Effects of endothelin receptor blockade
Chronic endothelin A/B-blockade and
endothelium-dependent relaxation
Co-administration of bosentan on top of torcetrapib (SHR-T/B)
for 3 weeks restored endothelium-dependent relaxations in
SHR-T (P, 0.01 vs. SHR-T/B) (Figure 8). The EC50 values
(2log[M]) of SHR-T, SHR-P, and SHR-T/B were: 7.903, 8.126,
and 7.949, respectively (P, 0.001 SHR-T vs. SHR-P). With bosen-
tan, the area under the curve was increased (+11.63%, P, 0.05
vs. SHR-T, Table 3). Furthermore, maximal relaxation to ACh
increased as well with bosentan (Table 3).
Endothelin A and B receptors’ antagonism and
endothelin-1-induced contraction
Pre-treatment with the selective ETA receptor antagonist, BQ-123,
did not change ET-1-induced contractions of aortic rings. In par-
ticular, no difference between SHR-T and SHR-P was observed.
After pre-incubation with the selective ETB receptor antagonist,
BQ-788, ET-1 induced contraction in SHR-T rings remained
unchanged, while rings from SHR-P showed a trend in diminished
responses to ET-1 at 1028 M (see Supplementary material online,
Figure S4A and B).
Activity of the renin–angiotensin–aldosterone system
Plasma aldosterone was increased in SHR-T (+33.72%, P ¼ 0.0172
vs. SHR-P, see Supplementary material online, Figure S5C), but
remained unchanged within the WKY groups (data not shown).
A higher trend in plasma renin activity was found in SHR-T
when compared with SHR-P, but not statistically significant. No
difference in angiotensin II was found between SHR-T and SHR-P
(see Supplementary material online, Figure S5A and B).
Discussion
This study demonstrates that the CETP inhibitor torcetrapib
induces a sustained and marked impairment of endothelial func-
tion, decreases eNOS mRNA and protein as well as NO release,
stimulates aldosterone secretion as well as vascular ROS and ET
production.
The increased cardiovascular events in the ILLUMINATE trial
suggested potential off-target effects of torcetrapib.8 Indeed, BP
elevation was paralleled by an increase in plasma aldosterone,
bicarbonate and sodium as well as a reduction in plasma potassium
were observed in ILLUMINATE trial.8 Since endothelium-derived
NO plays a crucial role in the maintenance of endothelial and vas-
cular function23 and decreased NO production has been impli-
cated in the pathogenesis and clinical course of all known
cardiovascular diseases and is associated with future risk of
adverse cardiovascular events,24 –26 the effects of torcetrapib on
endothelial function in the aorta of SHRs and WKY rats were
investigated. SHR treated with torcetrapib showed a marked
impairment in ACh-induced endothelial-dependent relaxations,
which may represent a clinically relevant mechanism. Interestingly,
torcetrapib also down-regulated eNOS mRNA and protein
expression in SHR aortas in vivo and decreased direct NO
release in HAECs in vitro, indicating an inhibition of eNOS
expression as well as inactivation of NO by torcetrapib. Intrigu-
ingly, torcetrapib stimulated the vascular production of reactive
oxygen species in SHR-T. Since the link between increased oxi-
dative stress and reduced bioavailability of NO has been well
established,27,28 the present results indicate that oxidative stress
Figure 7 Aortic endothelin-1 tissue content as determined by
radioimmunoassay. Torcetrapib-treated spontaneously hyperten-
sive rats showed higher aortic tissue levels of endothelin-1 when
compared with placebo-treated spontaneously hypertensive rats.
P, 0.05.
Figure 8 Endothelium-dependent relaxation to acetylcholine
in isolated aortic rings pre-contracted with norepinephrine
obtained from spontaneously hypertensive rats treated with tor-
cetrapib (SHR-T), placebo spontaneously hypertensive rats
(SHR-P), and spontaneously hypertensive rats co-administered
with torcetrapib plus the endothelin A/B-receptor antagonist
bosentan (SHR-T/B). Acetylcholine-induced vasorelaxation was
impaired in aortas of SHR-T in comparison to placebo-treated
spontaneously hypertensive rats (SHR-P) while co-administration
of endothelin receptor antagonist bosentan normalized endo-
thelial function. SHR-T vs. SHR-P: *P, 0.05 for 1029 and 1025
and P, 0.005 for 1028 to 1026 M acetylcholine; SHR-T vs.
SHR-T/B: *P, 0.01 for 1027–1025 M acetylcholine.
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accounts in parts for the impairment of endothelial function
induced by torcetrapib.
Interestingly, torcetrapib increased both vascular reactivity to
ET-1 and aortic ET-1 tissue, indicating an activation of the vascular
ET system by torcetrapib in SHR. Endothelin-1, a potent endo-
thelial vasoconstrictor peptide formed by endothelial cells,29
impacts on salt and water homeostasis and stimulates the renin–
angiotensin–aldosterone system and plays a pivotal role in vascular
remodelling in experimental and human hypertension.30,31 To
further delineate the mechanisms of ET-1-induced changes on
endothelium-dependent vasorelaxation in SHR-T, torcetrapib
was administered to SHR and, in parallel, co-administered
the ETA/B-receptor antagonist bosentan. Of note, chronic
ETA/B-receptor blockade normalized endothelium-dependent
relaxations, indicating that the stimulation of ET-1 is crucially
involved in endothelial dysfunction induced by torcetrapib.32
Indeed, NO and ET-1 interact with each other both at their site
of production in endothelial cells29 as well as at their site of
action, i.e. in smooth muscle cells.33 Hence it is likely that ET-1
down-regulates eNOS expression and stimulates ROS and in
turn reduces NO bioavailability and endothelium-dependent
relaxations.
Endothelin-1 modulates biological responses through at least
two distinct types of receptors, i.e. ETA and ETB receptors.
Endothelin A receptors are predominantly located on
VSMCs,34,35 whereas ETB receptors are expressed both on
VSMCs and on endothelial cells.36– 38 To delineate a possible
role of an up-regulation of ET-1 receptors in the observed
increased contractile response to ET-1 in SHR-T, aortas obtained
from SHR-T and SHR-P were pre-treated with the selective antag-
onists ETA and ETB receptors BQ-123 and BQ-788, respectively.
However, these experiments revealed no difference of
ET-1-induced contraction between SHR-T and SHR-P, suggesting
a similar contribution of both receptors to ET-1-induced contrac-
tion both in the presence and in the absence of torcetrapib. Simi-
larly, aortic mRNA expression of ETA and ETB receptors as
assessed by RT–PCR did not reveal differences between SHR-T
and SHR-P. Likewise, in aortic tissue obtained from all groups of
animals, no significant change in receptor distribution between
either VSMCs or endothelial cells could be demonstrated by
immunohistochemistry. This indicates that torcetrapib-induced
changes in the response to ET-1 are not related to different
expression levels of ETA and ETB receptors and/or their distri-
bution in VSCMs or endothelial cells, but may involve different
calcium handling in VSMCs. Indeed, torcetrapib appears to activate
L-type calcium channels in VSMCs39 and inhibition of these chan-
nels blunts the response to the peptide in rodents40 and in
humans.41
The increase in ET-1 tissue levels in SHR-T was paralleled by an
increase in plasma aldosterone, but not renin or angiotension II
levels pointing towards a direct and specific activation of the
mineralcorticoid axis by ET-1. Indeed, ET-1 is a potent secretago-
gue of aldosterone within adrenal glands.42 –44 The present study
supports and extends recent findings by Forrest et al.,45 as we
here demonstrate a transient BP and concomitant and sustained
increase in plasma aldosterone after torcetrapib treatment. As
BP returned to baseline, the latter phenomenon suggests an aldos-
terone escape at the level of the kidney and/or resistance vessels.
The impairment of endothelial function is likely to represent an
off-target effect of torcetrapib and unrelated to CETP inhibition, as
rodents such as the rat are lacking CETP46 and lipids remained
unchanged under the conditions of the present study. Conversely,
in humans, HDL increases the eNOS protein expression thereby
off-setting LDL-induced inhibition of eNOS expression in dyslipi-
daemia and intravenous administration of reconstituted HDL into
the human forearm circulation restored ACh-induced endothelial
function and flow-mediated vasodilation in hypercholesterolemic
patients.47 Importantly, we just recently demonstrated that CETP
inhibition with dalcetrapib (formerly JTT-705) increased HDL-C
and lowered triglycerides but similarly failed to improve endo-
thelial function.17 A modest improvement of endothelium-depen-
dent vasodilatation, howewever, was found in the subgroup of
patients with low baseline HDL only.
Interestingly, all off-target effects of torcetrapib effects became
apparent in SHR only, but not in normotensive WKY rats. This
suggests that potential deleterious effects of torcetrapib in the vas-
culature come into play only with a genetic disposition or presence
of arterial hypertension. This is in line with early data on the BP
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Table 3 The endothelial parameters analysed in torcetrapib-treated spontaneously hypertensive rats (SHR-T), placebo
spontaneously hypertensive rats (SHR-P), and torcetrapib plus bosentan-treated spontaneously hypertensive rats
(SHR-T/B).
Parameter SHR-T SHR-P SHR-T/B
Acetylcholine
Area under the curve 214.9+5.315* 258.1+7.467 239.9+6.505**
EC50 (M), 2log 7.903+0.006
† 8.126+0.054 7.949+0.046
Maximum (%) 76.62+2.025‡ 84.11+1.481 83.10+1.312}
*P, 0.01 SHR-T vs. SHR-P;
**P, 0.05 SHR-T vs. SHR-T/B;
†P, 0.01 SHR-T vs. SHR-P;
‡P, 0.01 SHR-T vs. SHR-P;
}P, 0.05 SHR-T vs. SHR-T/B.
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effects of torcetrapib in 162 patients with low HDL levels12 in
which torcetrapib at doses up to 90 mg/day did not increase BP
compared with placebo during a treatment period of up to 8
weeks. Interestingly and in line with the former interpretation of
our data, all patients of this study were normotensive at baseline
with average office BP values of 123/78 mmHg.12
The BP effects alone, however, do not explain the excess of
cardiovascular risk associated with long-term treatment with
torcetrapib. However, more than 70% of all patients included in
the ILLUMINATE trial had a history of hypertension, while patients
with uncontrolled hypertension were excluded from the trial.
Nevertheless, hypertension was still the most frequently observed
adverse event (18.7% in the torcetrapib vs. 7.5% in the placebo
group).8
The specific off-target effects of torcetrapib described in this
study, in particular the sustained and marked impairment of endo-
thelial function, decreased NO-bioavailability and increased ROS
production as well as activation of the ET, aldosterone, may at
least in part explain the increased mortality associated with torcetra-
pib treatment in the ILLUMINATE trial. Thus, careful assessment of
vascular toxicity is mandatory for the development of other CETP
inhibitors. Indeed, as outlined by Pfeffer and Sacks,48 studies with
surrogate endpoints, such as lipids or vascular imaging studies,
remain hypothesis generating at best and cannot provide sufficient
safety information. Therefore, the question whether CETP inhibition
has atheroprotective or proatherogenic role in humans may be
answered only when ongoing adequately powered randomized
morbidity and mortality trials are completed. Although novel
CETP inhibitors such as dalcetrapib and anacetrapib up to now did
not appear to have off-target adverse effects on BP and adrenal func-
tion, their vascular protective effects are far from established.49
Since the results of the present study unequivocally demonstrate
substantial off-target effects of one of the members of the class of
CETP inhibitors unrelated to CETP inhibition, the absence of evi-
dence does not provide evidence of the absence of such off-target
effects with the other members of the class. Importantly, BP is unli-
kely to explain all of the excess morbidity and mortality associated
with the use of torcetrapib. Indeed, in the present study, substantial
impairment of endothelial function was still present after 3 weeks, a
long time after BP already had returned to baseline. As such, the
results of the just recently presented DEFINE trial50 need to be
put in perspective, as the absence of a BP increase associated with
the use of anacetrapib does not allow to exclude BP independent off-
target effects, endothelial impairment in particular.
Whether and to what degree these unpredicted and poten-
tially deleterious off-target effects are molecule-specific or rep-
resent a class effect of CETP inhibitors needs to be ruled out
in the clinical development of other CETP inhibitors, such as
anacetrapib and dalcetrapib before a large patient population,
particularly when at increased cardiovascular risk, is exposed
to these compounds.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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